Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study

Scholar Rock SRRK revealed results on Wednesday from the Phase 2 EMBRAZE proof-of-concept trial assessing apitegromab in combination with tirzepatide to preserve lean mass during tirzepatide-induced weight loss.Tirzepatide is an active ingredient in Eli Lilly And Co’s LLY widely used Mounjaro and Zepbound for diabetes and weight loss, respectively.The trial demonstrated that 30% of the total weight loss with tirzepatide alone was due to lean mass loss.Apitegromab therapy (10 mg/kg) with tripeptide preserved ...